AFM
NRXP icon

Anson Funds Management’s NRX Pharmaceuticals NRXP Stock Holding History

Anson Funds Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,043,957
Closed -$8.25M – 163
2025
Q4 		$8.25M Buy
3,043,957
+1,018,853
+50% +$2.73M 0.78% 34
2025
Q3 		$6.68M Buy
2,025,104
+420,129
+26% +$1.2M 0.61% 34
2025
Q2 		$5.23M Buy
1,604,975
+425,914
+36% +$1.07M 0.75% 29
2025
Q1 		$2.42M Buy
1,179,061
+993,401
+535% +$2.8M 0.44% 51
2024
Q4 		$408K Buy
185,660
+43,135
+30% +$58K 0.04% 122
2024
Q3 		$241K Buy
+142,525
New +$287K 0.02% 135

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Anson Funds Management's NRXP Position: Q1 2026 in Review

Anson Funds Management sold out of NRX Pharmaceuticals (NRXP) in Q1 2026, closing a stake of 3,043,957 shares — an estimated $8.25M sold.

Anson Funds Management first reported a position in NRXP in Q3 2024 and held it in 6 quarters. The position peaked at $8.25M in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Anson Funds Management reported no remaining NRX Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Anson Funds Management sold 3,043,957 NRX Pharmaceuticals shares in Q1 2026, an estimated $8.25M.
  • Anson Funds Management first reported a position in NRX Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Anson Funds Management's NRX Pharmaceuticals position peaked at $8.25M in Q4 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Anson Funds Management's 13F filing for Q1 2026, filed 14 May 2026.